7.      References

[1] A. Elshaug, ‘Appropriate Use Criteria’, 2016.

[2] M. R. U. Department of Health, ‘MBS data’.

[3] A. B. of Statistics, ‘Australian Demographic Statistics’, 3101.0 - Australian Demographic statistics Jun 2010 and Jun 2015. [Online]. Available: http://www.abs.gov.au/ausstats/abs@.nsf/Previousproducts/3101.0Main Features1Jun 2015?opendocument&tabname=Summary&prodno=3101.0&issue=Jun 2015&num=&view=. [Accessed: 25-Apr-2016].

[4] N. I. for H. and C. E. NICE, ‘Phototherapy for Psoriasis’, 2016. [Online]. Available: http://pathways.nice.org.uk/pathways/psoriasis#path=view%3A/pathways/psoriasis/phototherapy-for-psoriasis.xml&content=view-node%3Anodes-risk-of-skin-cancer. [Accessed: 20-May-2016].

[5] D. J. Gawkrodger, A. D. Ormerod, L. Shaw, I. Mauri-Sole, M. E. Whitton, M. J. Watts, A. V Anstey, J. Ingham, K. Young, Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists, Clinical Standards Department, Royal College of Physicians of London, Cochrane Skin Group, and Vitiligo Society, ‘Guideline for the diagnosis and management of vitiligo.’, Br. J. Dermatol., vol. 159, no. 5, pp. 1051–76, Nov. 2008.

[6] R. M. R. Hearn, A. C. Kerr, K. F. Rahim, J. Ferguson, and R. S. Dawe, ‘Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.’, Br. J. Dermatol., vol. 159, no. 4, pp. 931–5, Sep. 2008.

[7] M. R. U. Department of Health, ‘MBS data - Q20396’.

[8] E. A. Olsen, E. Hodak, T. Anderson, J. B. Carter, M. Henderson, K. Cooper, and H. W. Lim, ‘Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium’, J. Am. Acad. Dermatol., vol. 74, no. 1, pp. 27–58, 2016.

[9] A. G. Elshaug, A. M. Watt, L. Mundy, and C. D. Willis, ‘Over 150 potentially low-value health care practices: an Australian study’, Med. J. Aust., vol. 197, no. 10, pp. 556–560 (Appendix), Nov. 2012.

[10] M. R. U. Department of Health, ‘MBS data - Q20214’, 2016.

[11] M. R. U. Department of Health, ‘MBS data - Q20423’, 2016.

[12] M. R. U. Department of Health, ‘MBS Data - COGNOS’, 2016.

[13] M. R. U. Department of Health, ‘MBS Data - Q20285’, 2016.

[14] M. R. U. Department of Health Australlia, ‘MBS data - Q20360’, 2016.

[15] H. A. Sampson, S. Aceves, S. A. Bock, J. James, S. Jones, D. Lang, K. Nadeau, A. Nowak-Wegrzyn, J. Oppenheimer, T. T. Perry, C. Randolph, S. H. Sicherer, R. A. Simon, B. P. Vickery, R. Wood, D. Bernstein, J. Blessing-Moore, D. Khan, R. Nicklas, J. Portnoy, D. Schuller, S. Spector, S. A. Tilles, and D. Wallace, ‘Food allergy: A practice parameter update - 2014’, J. Allergy Clin. Immunol., vol. 134, no. 5, pp. 1016–1025.e43, 2014.

[16] N. J. Osborne, J. J. Koplin, P. E. Martin, L. C. Gurrin, A. J. Lowe, M. C. Matheson, A. L. Ponsonby, M. Wake, M. L. K. Tang, S. C. Dharmage, and K. J. Allen, ‘Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants’, J. Allergy Clin. Immunol., vol. 127, no. 3, pp. 668–676, 2011.

[17] M. A. Kaliner, S. Del Giacco, C. D. Crisci, A. J. Frew, G. Liu, J. Maspero, H.-B. Moon, T. Nakagawa, P. C. Potter, L. J. Rosenwasser, A. B. Singh, E. Valovirta, P. Van Cauwenberge, and J. O. Warner, ‘Requirements for Physician Competencies in Allergy: Key Clinical Competencies Appropriate for the Care of Patients With Allergic or Immunologic Diseases’, World Allergy Organ. J., vol. 1, no. 2, pp. 42–46, 2008.

[18] A. Berger, ‘Skin prick testing: for the diagnosis of allergic disease, a manual for practitioners’, BMJ, vol. 325, no. 7361, p. 414, 2002.

[19] G. Du Toit, G. Roberts, P. H. Sayre, H. T. Bahnson, S. Radulovic, A. F. Santos, H. A. Brough, D. Phippard, M. Basting, M. Feeney, V. Turcanu, M. L. Sever, M. Gomez Lorenzo, M. Plaut, and G. Lack, ‘Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy’, http://dx.doi.org/10.1056/NEJMoa1414850, 2015.

[20] M. M. Lipke, ‘An armamentarium of wart treatments’, Clin. Med. Res., vol. 4, no. 4, pp. 273–293, 2006.

[21] J. C. Sterling, S. Gibbs, S. S. Haque Hussain, M. F. Mohd Mustapa, and S. E. Handfield-Jones, ‘British Association of Dermatologists’ guidelines for the management of cutaneous warts 2014’, Br. J. Dermatol., no. Agree Ii, pp. 696–712, 2014.

[22] C. S. Kwok, S. Gibbs, C. Bennett, R. Holland, and R. Abbott, ‘Topical treatments for cutaneous warts.’, Cochrane database Syst. Rev., no. 9, p. CD001781, 2012.

[23] H. Wat, D. C. Wu, J. Rao, and M. P. Goldman, ‘Application of intense pulsed light in the treatment of dermatologic disease: A systematic review’, Dermatologic Surg., vol. 40, no. 4, pp. 359–377, 2014.

[24] E. G. Butler, S. D. McClellan, and E. V. Ross, ‘Split treatment of photodamaged skin with KTP 532 nm laser with 10 mm handpiece versus IPL: a cheek-to-cheek comparison.’, Lasers Surg. Med., vol. 38, no. 2, pp. 124–8, Feb. 2006.

[25] G. Dinsdale, A. Murray, T. Moore, J. Ferguson, J. Wilkinson, H. Richards, C. E. M. Griffiths, and A. L. Herrick, ‘A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial.’, Rheumatology (Oxford)., vol. 53, no. 8, pp. 1422–30, Aug. 2014.

[26] P. Fioramonti, P. Fino, I. Ponzo, M. Ruggieri, and M. G. Onesti, ‘Intense pulsed light in the treatment of telangiectasias: Case report of Behçet’s disease with superficial vascular involvement’, http://dx.doi.org/10.3109/14764172.2013.854634, 2013.

[27] L. Fodor, Y. Ramon, A. Fodor, N. Carmi, I. J. Peled, and Y. Ullmann, ‘A side-by-side prospective study of intense pulsed light and Nd:YAG laser treatment for vascular lesions.’, Ann. Plast. Surg., vol. 56, no. 2, pp. 164–70, Feb. 2006.

[28] R. Kassir, A. Kolluru, and M. Kassir, ‘Intense pulsed light for the treatment of rosacea and telangiectasias.’, J. Cosmet. Laser Ther., vol. 13, no. 5, pp. 216–22, Oct. 2011.

[29] P. Nymann, L. Hedelund, and M. Haedersdal, ‘Intense pulsed light vs. long-pulsed dye laser treatment of telangiectasia after radiotherapy for breast cancer: a randomized split-lesion trial of two different treatments.’, Br. J. Dermatol., vol. 160, no. 6, pp. 1237–41, Jun. 2009.

[30] P. Nymann, L. Hedelund, and M. Haedersdal, ‘Long-pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: a randomized controlled trial.’, J. Eur. Acad. Dermatol. Venereol., vol. 24, no. 2, pp. 143–6, Feb. 2010.

[31] E. V. Ross, M. Smirnov, M. Pankratov, and G. Altshuler, ‘Intense pulsed light and laser treatment of facial telangiectasias and dyspigmentation: some theoretical and practical comparisons.’, Dermatol. Surg., vol. 31, no. 9 Pt 2, pp. 1188–98, Sep. 2005.

[32] E. A. Tanghetti, ‘Split-face randomized treatment of facial telangiectasia comparing pulsed dye laser and an intense pulsed light handpiece.’, Lasers Surg. Med., vol. 44, no. 2, pp. 97–102, Feb. 2012.

[33] E. Tanghetti, J. Q. Del Rosso, D. Thiboutot, R. Gallo, G. Webster, L. F. Eichenfield, L. Stein-Gold, D. Berson, A. Zaenglein, and American Acne & Rosacea Society, ‘Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 4: a status report on physical modalities and devices.’, Cutis, vol. 93, no. 2, pp. 71–6, Feb. 2014.

[34] H. Wat, D. C. Wu, J. Rao, and M. P. Goldman, ‘Application of intense pulsed light in the treatment of dermatologic disease: a systematic review.’, Dermatol. Surg., vol. 40, no. 4, pp. 359–77, Apr. 2014.

[35] R. A. Weiss, E. V. Ross, E. A. Tanghetti, D. B. Vasily, J. J. Childs, M. Z. Smirnov, and G. B. Altshuler, ‘Characterization of an optimized light source and comparison to pulsed dye laser for superficial and deep vessel clearance.’, Lasers Surg. Med., vol. 43, no. 2, pp. 92–8, Feb. 2011.

[36] S. M. Connolly, D. R. Baker, B. M. Coldiron, M. J. Fazio, P. A. Storrs, A. T. Vidimos, M. J. Zalla, J. D. Brewer, W. Smith Begolka, T. G. Berger, M. Bigby, J. L. Bolognia, D. G. Brodland, S. Collins, T. A. Cronin Jr., M. V. Dahl, J. M. Grant-Kels, C. W. Hanke, G. J. Hruza, W. D. James, C. W. Lober, E. I. McBurney, S. A. Norton, R. K. Roenigk, R. G. Wheeland, and O. J. Wisco, ‘AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Su’, J. Am. Acad. Dermatol., vol. 67, no. 4, pp. 531–550, 2012.

[37] A. Pollack, M. McGrath, J. Henderson, and H. Britt, ‘Skin cancer by state and territory’, Aust. Fam. Physician, vol. 43, no. 8, p. 507, 2014.

[38] R. N. Werner, E. Stockfleth, S. M. Connolly, O. Correia, R. Erdmann, P. Foley, A. K. Gupta, A. Jacobs, H. Kerl, H. W. Lim, G. Martin, M. Paquet, D. M. Pariser, S. Rosumeck, H.-J. Röwert-Huber, A. Sahota, O. P. Sangueza, S. Shumack, B. Sporbeck, N. A. Swanson, L. Torezan, and A. Nast, ‘Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version.’, J. Eur. Acad. Dermatol. Venereol., vol. 29, no. 11, pp. 2069–79, Nov. 2015.

[39] R. R. Anderson, M. B. Donelan, C. Hivnor, E. Greeson, E. V. Ross, P. R. Shumaker, N. S. Uebelhoer, and J. S. Waibel, ‘Laser treatment of traumatic scars with an emphasis on ablative fractional laser resurfacing: consensus report.’, JAMA dermatology, vol. 150, no. 2, pp. 187–93, Feb. 2014.

[40] J. Preissig, K. Hamilton, and R. Markus, ‘Current Laser Resurfacing Technologies: A Review that Delves Beneath the Surface.’, Semin. Plast. Surg., vol. 26, no. 3, pp. 109–16, Aug. 2012.

[41] E. T. Weiss, J. A. Brauer, R. Anolik, K. K. Reddy, J. K. Karen, E. K. Hale, L. A. Brightman, L. Bernstein, and R. G. Geronemus, ‘1927-nm Fractional resurfacing of facial actinic keratoses: A promising new therapeutic option’, J. Am. Acad. Dermatol., vol. 68, no. 1, pp. 98–102, 2013.